Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.

Abstract

PURPOSE:

Adjuvant chemotherapy for breast cancer can be associated with a variety of side effects, one of which is the induction of premature menopause in premenopausal patient. Although taxanes have increasingly been used in the adjuvant setting, there has been relatively little published on the frequency of amenorrhea related to their use.

PATIENTS AND METHODS:

We review records of 159 premenopausal patients receiving adjuvant chemotherapy from our practice.

RESULTS:

Altogether, 51% of all patients retained menstrual function after chemotherapy.

CONCLUSION:

It was observed that patients receiving adjuvant anthracycline-based chemotherapy with sequential taxane therapy did not have a higher rate of amenorrhea than those not receiving a taxane.

• Authors: Amy L Davis, Matthew Klitus, David M Mintzer
• Journal: Clinical breast cancer (Clin Breast Cancer) Vol. 6 Issue 5 Pg. 421-4 (Dec 2005) ISSN: 1526-8209 [Print] United States
• PMID: 16381625 (Publication Type: Journal Article)

Chemical References

• Anthracyclines
• Antineoplastic Agents, Phytogenic
• Taxoids
• Tamoxifen
• Paclitaxel

Topics

• Adolescent
• Adult
• Age Factors
• Age of Onset
• Amenorrhea (chemically induced)
• Anthracyclines (therapeutic use)
• Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, epidemiology)
• Chemotherapy, Adjuvant (adverse effects)
• Female
• Humans
• Menstruation (drug effects)
• Middle Aged
• Paclitaxel (adverse effects, therapeutic use)
• Retrospective Studies
• Tamoxifen (therapeutic use)
• Taxoids (adverse effects, therapeutic use)